Withholding or continuing angiotensin-converting enzyme inhibitors or angiotensin 2 receptor blockers on acute kidney injury after non-cardiac surgery

IF 7.5 1区 医学 Q1 ANESTHESIOLOGY Anaesthesia Pub Date : 2024-08-11 DOI:10.1111/anae.16409
Marike Rademan, Conall Hayes, Aoife Lavelle
{"title":"Withholding or continuing angiotensin-converting enzyme inhibitors or angiotensin 2 receptor blockers on acute kidney injury after non-cardiac surgery","authors":"Marike Rademan,&nbsp;Conall Hayes,&nbsp;Aoife Lavelle","doi":"10.1111/anae.16409","DOIUrl":null,"url":null,"abstract":"<p>We read with interest the article by Choi et al., which examines the association between acute kidney injury in patients who have had their angiotensin-converting enzyme inhibitors or angiotensin receptor-blocking drugs withheld or continued, respectively, pre-operatively [<span>1</span>]. We commend them on a well-designed study that paid great attention to relevant propensity matching.</p><p>We want to comment on the difference between statistical significance and clinical relevance [<span>2</span>]. While we agree that an increase of 26.4 μmol.l<sup>-1</sup> in &lt; 48 h is the definition of acute kidney injury as set out by the Acute Kidney Injury Network, both groups show increased serum creatinine values in the postoperative period [<span>1, 3</span>]. The actual difference in increased serum creatinine values is relatively small between the two groups, which would lead us to question the clinical significance. In contrast, the statistical significance of those who breach the threshold of 26.4 μmol.l<sup>-1</sup> is clear and undeniable. As discussed in the article, a recent meta-analysis by Hollmann et al. failed to show an association between peri-operative administration of angiotensin-converting enzyme inhibitors or angiotensin receptor-blocking drugs and mortality or major adverse cardiac events in patients undergoing non-cardiac surgery [<span>3</span>].</p><p>While we agree that the article by Choi et al. supports the routine withholding of angiotensin-converting enzyme inhibitors and angiotensin receptor-blocking drugs pre-operatively, we think the more interesting question is whether we can identify specific subsets of patients who are more significantly impacted by the continuation of these drugs in the peri-operative period. This is addressed in the supplementary material where we see that the odds ratio of developing an acute kidney injury appears to be much greater in those patients who present for surgery with an elevated baseline creatinine, low baseline haemoglobin, low BMI and those requiring pre-operative red blood cell transfusion. We are interested if the authors, knowing the data in detail, have any opinion on whether they see a need to cancel surgery in the higher-risk cohort of patients who erroneously continue these drugs peri-operatively.</p><p>The authors report that continuation of these drugs was associated with a mean reduction in intra-operative mean arterial pressure of 1.3 mmHg. While this has reached statistical significance, again, we question its clinical relevance. The patients who had these medications withheld also had a relatively large increase in baseline creatinine levels in the postoperative period. The difference in mean arterial pressure, fluid boluses and vasopressor administration between the groups was statistically significant but, again, we question the clinical significance.</p><p>The authors highlight that the type of maintenance of anaesthesia (volatile, total intravenous or even neuraxial techniques), sex of the patient and the type of surgery could potentially contribute to postoperative renal dysfunction. However, there were more male patients enrolled in the study (58%), more patients received volatile anaesthetic maintenance (75%) and there was no difference between the two groups. Oh et. al. performed a retrospective propensity score analysis showing no significant difference in postoperative acute kidney injuries between patients who received total intravenous anaesthesia and those who received sevoflurane-based inhalational anaesthesia [<span>4</span>]. This raises the question of whether these variables were clinically and statistically significant enough to be mentioned in this study.</p><p>While the primary outcome of the study by Choi et al. is relevant and an important addition to the literature, the supplementary material poses more interesting questions. Is the key to showing the actual effect of withholding these medications not seen because we are including cohorts of patients with greater renal functional reserve? If the data were further dissected to look at the impact of baseline values, we may find where the true clinical significance of this study lies.</p>","PeriodicalId":7742,"journal":{"name":"Anaesthesia","volume":"79 12","pages":"1379-1380"},"PeriodicalIF":7.5000,"publicationDate":"2024-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/anae.16409","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anaesthesia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/anae.16409","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

We read with interest the article by Choi et al., which examines the association between acute kidney injury in patients who have had their angiotensin-converting enzyme inhibitors or angiotensin receptor-blocking drugs withheld or continued, respectively, pre-operatively [1]. We commend them on a well-designed study that paid great attention to relevant propensity matching.

We want to comment on the difference between statistical significance and clinical relevance [2]. While we agree that an increase of 26.4 μmol.l-1 in < 48 h is the definition of acute kidney injury as set out by the Acute Kidney Injury Network, both groups show increased serum creatinine values in the postoperative period [1, 3]. The actual difference in increased serum creatinine values is relatively small between the two groups, which would lead us to question the clinical significance. In contrast, the statistical significance of those who breach the threshold of 26.4 μmol.l-1 is clear and undeniable. As discussed in the article, a recent meta-analysis by Hollmann et al. failed to show an association between peri-operative administration of angiotensin-converting enzyme inhibitors or angiotensin receptor-blocking drugs and mortality or major adverse cardiac events in patients undergoing non-cardiac surgery [3].

While we agree that the article by Choi et al. supports the routine withholding of angiotensin-converting enzyme inhibitors and angiotensin receptor-blocking drugs pre-operatively, we think the more interesting question is whether we can identify specific subsets of patients who are more significantly impacted by the continuation of these drugs in the peri-operative period. This is addressed in the supplementary material where we see that the odds ratio of developing an acute kidney injury appears to be much greater in those patients who present for surgery with an elevated baseline creatinine, low baseline haemoglobin, low BMI and those requiring pre-operative red blood cell transfusion. We are interested if the authors, knowing the data in detail, have any opinion on whether they see a need to cancel surgery in the higher-risk cohort of patients who erroneously continue these drugs peri-operatively.

The authors report that continuation of these drugs was associated with a mean reduction in intra-operative mean arterial pressure of 1.3 mmHg. While this has reached statistical significance, again, we question its clinical relevance. The patients who had these medications withheld also had a relatively large increase in baseline creatinine levels in the postoperative period. The difference in mean arterial pressure, fluid boluses and vasopressor administration between the groups was statistically significant but, again, we question the clinical significance.

The authors highlight that the type of maintenance of anaesthesia (volatile, total intravenous or even neuraxial techniques), sex of the patient and the type of surgery could potentially contribute to postoperative renal dysfunction. However, there were more male patients enrolled in the study (58%), more patients received volatile anaesthetic maintenance (75%) and there was no difference between the two groups. Oh et. al. performed a retrospective propensity score analysis showing no significant difference in postoperative acute kidney injuries between patients who received total intravenous anaesthesia and those who received sevoflurane-based inhalational anaesthesia [4]. This raises the question of whether these variables were clinically and statistically significant enough to be mentioned in this study.

While the primary outcome of the study by Choi et al. is relevant and an important addition to the literature, the supplementary material poses more interesting questions. Is the key to showing the actual effect of withholding these medications not seen because we are including cohorts of patients with greater renal functional reserve? If the data were further dissected to look at the impact of baseline values, we may find where the true clinical significance of this study lies.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
暂停或继续使用血管紧张素转换酶抑制剂或血管紧张素 2 受体阻滞剂对非心脏手术后急性肾损伤的影响。
我们饶有兴趣地阅读了 Choi 等人的文章,他们研究了术前分别停用或继续使用血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂的患者急性肾损伤之间的关联[1]。我们想就统计学意义和临床相关性之间的区别发表意见[2]。虽然我们同意急性肾损伤网络(Acute Kidney Injury Network)对急性肾损伤的定义是 48 小时内血清肌酐升高 26.4 μmol.l-1,但两组患者术后血清肌酐值均升高[1, 3]。两组患者血清肌酐值增加的实际差异相对较小,因此我们会质疑其临床意义。相比之下,那些突破 26.4 μmol.l-1 临界值的患者在统计学上的意义是显而易见且不可否认的。正如文章中所讨论的,Hollmann 等人最近的一项荟萃分析未能显示在接受非心脏手术的患者中,围手术期服用血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂与死亡率或主要不良心脏事件之间存在关联[3]。虽然我们同意 Choi 等人的文章支持术前常规暂停使用血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂,但我们认为更有趣的问题是,我们是否能确定哪些特定的患者亚群在围手术期继续使用这些药物会受到更严重的影响。补充材料中提到了这一问题,我们看到,基线肌酐升高、基线血红蛋白偏低、体重指数偏低以及术前需要输红细胞的患者发生急性肾损伤的几率似乎更大。我们感兴趣的是,作者在详细了解了这些数据后,是否认为有必要取消围手术期错误地继续使用这些药物的高风险患者的手术。作者报告说,继续使用这些药物与术中平均动脉压平均降低 1.3 mmHg 有关。虽然这具有统计学意义,但我们再次质疑其临床意义。术后停用这些药物的患者肌酐基线水平也有较大幅度的升高。作者强调,维持麻醉的类型(挥发性、全静脉或甚至神经轴技术)、患者性别和手术类型都有可能导致术后肾功能障碍。不过,该研究中男性患者较多(58%),接受挥发性麻醉维持的患者较多(75%),两组患者之间没有差异。Oh 等人进行了一项回顾性倾向评分分析,结果显示接受全静脉麻醉的患者与接受七氟醚吸入麻醉的患者在术后急性肾损伤方面没有明显差异[4]。这就提出了一个问题,即这些变量在临床和统计学上是否具有足够的意义,以至于在这项研究中被提及。虽然 Choi 等人研究的主要结果是相关的,是对文献的重要补充,但补充材料提出了更多有趣的问题。显示暂停这些药物的实际效果的关键是否在于我们纳入了肾功能储备更强的患者组群?如果对数据进行进一步剖析,研究基线值的影响,我们可能会发现这项研究真正的临床意义所在。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Anaesthesia
Anaesthesia 医学-麻醉学
CiteScore
21.20
自引率
9.30%
发文量
300
审稿时长
6 months
期刊介绍: The official journal of the Association of Anaesthetists is Anaesthesia. It is a comprehensive international publication that covers a wide range of topics. The journal focuses on general and regional anaesthesia, as well as intensive care and pain therapy. It includes original articles that have undergone peer review, covering all aspects of these fields, including research on equipment.
期刊最新文献
Breaking barriers: achieving equitable access to postoperative critical care Postoperative analgesic effectiveness of ultrasound-guided bilateral erector spinae plane block ‘Flextension’: a new term to describe optimal head and neck positioning for airway management Safety and efficacy of remimazolam tosilate for general anaesthesia in paediatric patients undergoing elective surgery: a multicentre, randomised, single-blind, controlled trial Evaluating tracheal intubation ergonomics: practitioner experience and laryngoscope type
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1